DYAIDYADIC INTERNATIONAL INC

Nasdaq dyadic.com


$ 1.92 $ 0.01 (0.51 %)    

Tuesday, 28-May-2024 15:48:13 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 1.96
$ 2.01
$ 0.00 x 0
$ 1.96 x 100
$ 1.88 - $ 2.01
$ 1.19 - $ 2.40
151,897
na
57.3M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-27-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dyadic-international-q1-eps-007-down-from-003-yoy-sales-33462k-down-from-97805k-yoy

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.07) per share. This is a 133.33 percent decrease over losse...

 dyadic-international-q4-eps-008-misses-006-estimate-sales-68653k-miss-80000k-estimate

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate o...

 earnings-scheduled-for-march-28-2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

 dyadic-publishes-c1-monoclonal-antibody-in-nonhuman-primate-study-in-nature-communications

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhum...

 dyadic-announces-strategic-partnership-agreement-to-develop-affordable-rabies-prophylactics-and-vaccines-using-its-c1-cell-microbial-protein-production-platform

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI...

 dyadic-announces-research-and-development-collaboration-agreement-with-global-biopharmaceutical-company-to-design-and-produce-recombinant-proteins-using-dyadics-c1-filamentous-fungal-based-microbial-protein-production-platform

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI...

 dyadic-announces-top-line-results-from-its-successful-phase-1-clinical-trial-for-a-first-in-human-filamentous-fungal-based-vaccine-candidate-primary-endpoint-met

Primary endpoint metDemonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both saf...

 hc-wainwright--co-reiterates-buy-on-dyadic-international-maintains-6-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Dyadic International (NASDAQ:DYAI) with a Buy and maintains $6 ...

 dyadic-international-q3-2023-eps-006-beats-007-estimate-sales-39706k-miss-80000k-estimate

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of ...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION